Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis

(2012) Kevin Hollevoet et al.   JOURNAL OF CLINICAL ONCOLOGY

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

(2012) R. J. Kelly et al.   MOLECULAR CANCER THERAPEUTICS

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

(2011) M. E. Mossoba et al.   CLINICAL CANCER RESEARCH

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

(2011) Kevin Hollevoet et al.   Journal of Thoracic Oncology

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

(2010) Kevin Hollevoet et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma

(2010) Paul Wheatley-Price et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

(2009) Raffit Hassan et al.   LUNG CANCER

High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

(2008) Y. Zhang et al.   CLINICAL CANCER RESEARCH